Saturday, October 31, 2026

Gyrodyne Already 4% Up, Almost One Hour Before The NASDAQ Open

ViaNews Editorial Team

February 15, 2023

Gyrodyne Already 4% Up, Almost One Hour Before The NASDAQ Open

(VIANEWS) - The NASDAQ opens in less than one hour and Gyrodyne's pre-market value is already 4.95% up.

Gyrodyne's last close was $8.48, 42.97% below its 52-week high of $14.87.

The last session, NASDAQ finished with Gyrodyne (GYRO) sliding 0% to $8.48. NASDAQ jumped 0.57% to $11,960.15, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session.

About Gyrodyne

Gyrodyne, LLC. owns, leases and manages diverse commercial properties. The firm is distinguished by its service-oriented philosophy toward property ownership and management. Gyrodyne has grown from a largely Long Island player during the past into a diversified East Coast presence with an emphasis on medical office product.

Earnings Per Share

As for profitability, Gyrodyne has a trailing twelve months EPS of $-2.53.

Moving Average

Gyrodyne's worth is under its 50-day moving average of $8.74 and way under its 200-day moving average of $10.56.

Volume

Today's last reported volume for Gyrodyne is 182 which is 83.69% below its average volume of 1116.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 2.74M for the twelve trailing months.

Yearly Top and Bottom Value

Gyrodyne's stock is valued at $8.48 at 08:42 EST, way below its 52-week high of $14.87 and above its 52-week low of $7.80.

More news about Gyrodyne (GYRO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com